TOLREMO therapeutics focuses on preventing non-genetic cancer drug resistance by dismantling cancer's earliest defense mechanisms to targeted therapies. Its lead clinical candidate, TT125-802, is an orally available small-molecule CBP/p300 bromodomain inhibitor designed to block transcriptional resistance pathways that drive early therapy escape. The company plans to initiate a Phase 1 monotherapy dose-escalation study to evaluate safety, pharmacokinetics, pharmacodynamics, and early signs of efficacy across solid tumor indications. Stepwise development will advance TT125-802 into combination studies with targeted agents such as KRAS, EGFR, or AR inhibitors in specific advanced solid tumors. TOLREMO positions its approach as a platform to improve response rates and durability of existing targeted treatments. The company is based in Basel, Switzerland, and has strengthened its leadership and advisory team alongside its clinical and development plans. TOLREMO is a Swiss biotech developing resistance‑preventing precision therapies that aim to complement standard cancer treatments. The company uses a proprietary drug discovery engine to identify novel drug‑resistance regulators and to develop small‑molecule therapies against those targets. Its therapies are designed to improve response rates, extend survival and enhance quality of life for cancer patients. Thanks to a Series A second closing, TOLREMO has secured additional capital to advance programs. The new funds are dedicated to development of the company’s first clinical candidate and to further strengthening its preclinical pipeline of resistance‑preventing assets. Stefanie Flückiger‑Mangual serves as CEO and co‑founder and commented on the financing and strategic progress. Tolremo Therapeutics is a Swiss biotechnology company advancing a science-based drug discovery and development pipeline focused on the molecular mechanisms of cancer and drug resistance. Founded in March 2017 as an ETH spin-off by Dr. Stefanie Flückiger-Mangual, Prof. Dr. Wilhelm Krek, Prof. Dr. Karl-Heinz Altmann, Dr. Isaac Kobrin and Emmanuel Savioz, the company leverages the founders' expertise in medicinal chemistry and pharmaceutical development. Its core programs comprise two major drug development programs aimed at preventing drug resistance in cancer therapies. Tolremo intends to use proceeds from the financing to further advance those programs. The company completed a CHF 9.0m (USD $9.3m) Series A financing. In conjunction with the funding the company strengthened its board by adding Dr. Erich Greiner, Prof. em. Thomas Cerny and Dr. Andreas Wallnöfer. TOLREMO is a biotech spin-off from ETH Zurich focused on preventing drug resistance in cancer therapy through science-based drug discovery and development. The company has developed a unique drug screening platform for which a patent has been filed. The platform is used both to discover novel anti-drug-resistance molecules and to identify new combinations of approved drugs to prevent resistance. TOLREMO plans to advance its discovery and development efforts and reach several key milestones within the next 12 to 18 months. The company benefits from access to ETH infrastructure, including laboratory space and an industry-standard robotic screening facility on the ETH Hönggerberg campus. Founded in March 2017, TOLREMO is led by CEO and co-founder Dr. Stefanie Flückiger-Mangual.

Total raised

$55M

Funding rounds

4

Latest round

Series A

Latest activity

Sep 2023